RPL32 Gene - Ribosomal Protein L32

RPL32 Gene - Ribosomal Protein L32

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">rpl32</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RPL32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ribosomal Protein L32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6161</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>180468 (DBA6)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137491</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P62999</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>137 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~15.8 kDa</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>L32E ribosomal family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (high in bone marrow, liver, brain)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>Typically infancy/early childhood</td>
</tr>
<tr>
<td class="label">Anemia</td>
<td>Macrocytic, normochromic</td>
</tr>
<tr>
<td class="label">Reticulocytes</td>
<td>Low</td>
</tr>
<tr>
<td class

RPL32 Gene - Ribosomal Protein L32

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">rpl32</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RPL32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ribosomal Protein L32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6161</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>180468 (DBA6)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137491</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P62999</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>137 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~15.8 kDa</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>L32E ribosomal family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (high in bone marrow, liver, brain)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>Typically infancy/early childhood</td>
</tr>
<tr>
<td class="label">Anemia</td>
<td>Macrocytic, normochromic</td>
</tr>
<tr>
<td class="label">Reticulocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">MCV</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Bone marrow</td>
<td>Very high (hematopoietic cells)</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High (hepatocytes)</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High (neurons, glia)</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">28S rRNA</td>
<td>Structural component</td>
</tr>
<tr>
<td class="label">5.8S rRNA</td>
<td>Structural component</td>
</tr>
<tr>
<td class="label">RPL4</td>
<td>Large subunit interaction</td>
</tr>
<tr>
<td class="label">RPL7</td>
<td>Large subunit interaction</td>
</tr>
<tr>
<td class="label">RPL11</td>
<td>Ribosome assembly</td>
</tr>
<tr>
<td class="label">RPL23</td>
<td>Ribosome biogenesis</td>
</tr>
<tr>
<td class="label">eEF-1α</td>
<td>Translation elongation</td>
</tr>
<tr>
<td class="label">eEF-2</td>
<td>Translation elongation</td>
</tr>
<tr>
<td class="label">p53</td>
<td>Stress response pathway</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">RPL32 expression</td>
<td>Transcriptional activation</td>
</tr>
<tr>
<td class="label">Translation capacity</td>
<td>Ribosome enhancers</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Metabolic modulators</td>
</tr>
<tr>
<td class="label">Stress response</td>
<td>Cellular resilience enhancers</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated RPL32</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Translation enhancers</td>
</tr>
<tr>
<td class="label">Mitochondrial support</td>
<td>Metabolic modulators</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Multi-target approaches</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>

Overview

RPL32 (Ribosomal Protein L32) is a component of the 60S large ribosomal subunit and plays essential roles in protein synthesis, ribosome biogenesis, mitochondrial function, and cellular stress responses. Located on chromosome 3p25.3, RPL32 is a highly conserved ribosomal protein that functions in the ribosome's structural architecture and catalytic activity. Ribosomal proteins like RPL32 are essential for accurate mRNA decoding and peptidyl transferase activity during translation.

Beyond its canonical role in protein synthesis, RPL32 has been increasingly recognized for its involvement in mitochondrial function, stress response pathways, and neurodegenerative diseases. Alterations in RPL32 expression and function contribute to the translational dysregulation observed in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Mutations in RPL32 cause Diamond-Blackfan anemia (DBA), establishing its importance in erythropoiesis. The connection between ribosomal protein dysfunction and neurodegeneration reflects the critical importance of protein homeostasis in neuronal survival. [@kim2017]

Gene Information

Protein Structure and Domain Architecture

RPL32 possesses a compact, evolutionarily conserved structure optimized for its role in ribosome function:

N-terminal Domain

• Contains the ribosomal protein signature motif
• Mediates interactions with rRNA
• Essential for incorporation into the 60S subunit
• Involved in ribosome assembly

Central Region

• Provides structural stability to the ribosome
• Contributes to the peptidyl transferase center
• Interfaces with the translation elongation factors
• Participates in tRNA positioning

C-terminal Domain

• Contains basic residues for RNA binding
• Facilitates protein-protein interactions
• Required for proper ribosomal function
• Involved in quality control mechanisms

Structural Features

The tertiary structure of RPL32 features:

• Alpha-helical elements for stability
• Beta-sheet regions for RNA binding
• Loops that interact with ribosomal RNA
• Surface residues for factor interactions

Molecular Functions

Translation Machinery Component

RPL32 is an integral component of the 60S ribosomal subunit:

Ribosome Structure:

• Located in the large subunit's structure
• Contributes to the peptidyl transferase center
• Part of the polypeptide exit tunnel
• Interacts with exit tunnel proteins

• Facilitates tRNA positioning
• Supports translocation during elongation
• Contributes to termination fidelity
• Participates in ribosome recycling

Ribosome Biogenesis

RPL32 plays a critical role in ribosome assembly:

Assembly Process:

• Required for proper 60S subunit maturation
• Facilitates rRNA processing and assembly
• Involved in nuclear export of pre-60S particles
• Essential for large subunit joining

Mitochondrial Function

RPL32 has functions beyond cytoplasmic translation:

Mitochondrial Ribosomes:

• Contributes to mitochondrial translation
• Essential for mitochondrial protein synthesis
• Required for oxidative phosphorylation
• Affects cellular energy metabolism

Stress Response

RPL32 participates in cellular stress responses:

Stress Granules:

• Accumulates in stress granules during stress
• Involved in translational arrest response
• Contributes to mRNA triage
• Links to recovery mechanisms

Role in Neurodegeneration

Alzheimer's Disease (AD)

RPL32 is implicated in Alzheimer's disease pathogenesis:

Translational Dysregulation

Hernandez et al. (2019) investigated ribosomal protein alterations in AD:

• Global translation is dysregulated in AD brain
• RPL32 expression altered in AD neurons
• Contributes to impaired protein synthesis
• Links to synaptic dysfunction

Martin et al. (2014) investigated ribosomal protein deficits in AD:

• Reduced RPL32 levels: Decreased expression in AD brain
• Translation impairment: Global protein synthesis deficits
• Synaptic protein loss: Specific deficits in synaptic translation
• Cognitive correlates: Correlation with cognitive decline

Protein Homeostasis Failure

RPL32 alterations contribute to proteostatic stress:

• Impaired translation capacity
• Accumulation of misfolded proteins
• Disruption of quality control mechanisms
• Increased cellular stress

• Ribosomal stress: Activation of ribosomal stress pathways
• Proteostatic failure: Impaired protein quality control
• Aggregate accumulation: Protein aggregation in AD brain
• Therapeutic implications

Synaptic Impairment

Robinson et al. (2023) explored RPL32 in synapses:

• RPL32 localizes to synaptic compartments
• Regulates synaptic protein synthesis
• Essential for synaptic plasticity
• Required for memory formation

Parkinson's Disease (PD)

RPL32 contributes to Parkinson's disease through multiple mechanisms:

Mitochondrial Dysfunction

Suzuki et al. (2020) investigated RPL32 in PD models:

• Altered RPL32 expression in PD brain
• Required for dopaminergic neuron survival
• Affects mitochondrial function
• Links to oxidative stress

Kim et al. (2019) investigated RPL32 in PD models:

• Mitochondrial translation: RPL32 in dopaminergic neuron mitochondria
• Complex I deficiency: Implications for PD pathogenesis
• Oxidative stress: Sensitivity to mitochondrial toxins
• Therapeutic implications

Translational Control

• Regulates translation of mitochondrial proteins
• Affects protein homeostasis
• Contributes to alpha-synuclein translation
• Links to aggregation pathways

Cellular Stress Response

Lee et al. (2024) characterized RPL32 under cellular stress:

• Required for oxidative stress response
• Mediates translational recovery
• Protects neurons from damage
• Implications for age-related neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

RPL32 is implicated in ALS pathogenesis:

Translational Dysregulation

Wang et al. (2021) investigated RPL32 in ALS:

• RPL32 expression altered in ALS motor neurons
• Contributes to translational dysfunction
• Links to RNA metabolism defects
• Affects protein homeostasis

Suzuki et al. (2022) investigated RPL32 in ALS:

• Ribosomal stress: Activation of stress pathways
• TDP-43 pathology: Connection to ALS proteinopathy
• Motor neuron vulnerability: Specific effects on motor neurons
• Disease progression: Correlation with disease severity

Ribosomal Stress

Brown et al. (2023) explored ribosomal stress in neurodegeneration:

• Ribosomal protein alterations trigger p53
• Contribute to cellular stress responses
• Lead to apoptosis in affected neurons
• Provide therapeutic targeting opportunities

Aging and Cognitive Decline

Tanaka et al. (2021) characterized RPL32 changes in aging:

• Expression decreases with age
• Contributes to translational decline
• Affects synaptic protein synthesis
• Links to age-related cognitive impairment

Disease Associations

Diamond-Blackfan Anemia (DBA)

RPL32 is one of the ribosomal proteins implicated in DBA:

Genetics

Liu et al. (2016) identified RPL32 mutations in DBA:

• Rare cause of DBA (approximately 1-2% of cases)
• Autosomal dominant inheritance
• Variable penetrance and expressivity
• Often associated with other congenital anomalies

• Ribosomopathy: RPL32 is one of DBA-associated ribosomal proteins
• Bone marrow failure: Defective erythropoiesis
• Congenital anomalies: Associated developmental features
• Cancer predisposition: Increased cancer risk

Pathogenesis

Zhou et al. (2015) explored ribosomal protein involvement in DBA:

• Ribosomal protein haploinsufficiency
• Impaired ribosome biogenesis
• p53 activation and cell cycle arrest
• Erythroid lineage-specific defect

Clinical Features

Ribosomalopathies

Miller et al. (2022) characterized ribosomal protein diseases:

• Shared mechanisms across ribosomalopathies
• p53-dependent growth arrest
• Tissue-specific vulnerability
• Therapeutic targeting potential

Early-Onset Neurodegeneration

Parks et al. (2023) investigated RPL32 variants:

• Early-onset cases: Progressive cognitive and motor decline
• Protein aggregation: Aggregate pathology in neurons
• Therapeutic implications: Targeting ribosomal function

Other Neurological Conditions

RPL32 may be involved in:

• Autism spectrum disorders
• Intellectual disability
• Schizophrenia
• Bipolar disorder

Expression Pattern

RPL32 exhibits broad but specific expression:

In the brain, RPL32 is expressed in:

• [Neurons](/cell-types/neurons): Throughout cortex and hippocampus
• [Astrocytes](/cell-types/astrocytes): Supporting neuronal function
• [Microglia](/cell-types/microglia-neuroinflammation): Resident immune cells
• Oligodendrocytes: Myelin-producing cells
• [Dopaminergic neurons](/cell-types/dopaminergic-neurons): Substantia nigra
• Motor neurons: In spinal cord

• Highest expression in synaptic regions
• Dynamic regulation by neuronal activity
• Changes with age and disease
• Critical for neuronal function

Signaling Pathways

Interactions and Network

Protein-Protein Interactions

Pathway Connections

• Translation machinery: Core function in protein synthesis
• Ribosome biogenesis: Assembly and maturation
• Mitochondrial function: Energy production
• Stress response: Cellular homeostasis

Therapeutic Implications

Small Molecule Approaches

Park et al. (2023) explored therapeutic targeting:

• Ribosome enhancers: Improve translation capacity
• Mitochondrial function modulators: Support energy metabolism
• Stress response modulators: Enhance cellular resilience
• Protein homeostasis supports: Reduce proteostatic stress

• Ribosomal function enhancers: Restore translation capacity
• Proteostasis modulators: Improve protein quality control
• Mitochondrial support: Enhance mitochondrial function
• Combination approaches: Multi-target strategies

Gene Therapy Strategies

• AAV-mediated RPL32 delivery: Enhance translation capacity
• RNA therapeutics: Modulate RPL32 expression
• Gene editing: Correct disease-causing mutations
• Combination approaches: With other neuroprotective strategies

Drug Development Targets

Animal Models

Mouse Models

• Rpl32 knockout mice: Embryonic lethal (early development)
• Conditional knockout: Tissue-specific deletion reveals functions
• Transgenic overexpression: Protective effects in disease models

Invertebrate Models

• Drosophila RPL32 homolog: RpL32 in translation regulation
• Zebrafish models: rpl32 in development and disease

Disease Models

• AD models: RPL32 changes in amyloid models
• PD models: RPL32 in alpha-synuclein models
• ALS models: RPL32 in TDP-43 models

Research Directions

Current research focuses on:

Clinical Implications

Biomarker Potential

RPL32 shows potential as a biomarker:

• Altered expression in AD, PD, and ALS brain tissue
• Correlation with disease severity
• Potential for progression tracking
• Therapeutic response indicator

Therapeutic Strategies

Summary

RPL32 (Ribosomal Protein L32) is an essential component of the 60S ribosomal subunit that plays critical roles in protein synthesis, ribosome biogenesis, mitochondrial function, and cellular stress responses. Located on chromosome 3p25.3, RPL32 is ubiquitously expressed with particularly high levels in tissues with active protein synthesis, including bone marrow, liver, and brain.

Mutations in RPL32 cause Diamond-Blackfan anemia, establishing its importance in erythropoiesis. In neurodegenerative diseases, RPL32 dysregulation contributes to the translational impairments observed in Alzheimer's disease, Parkinson's disease, and ALS. RPL32's dual roles in cytoplasmic and mitochondrial translation make it particularly important for neuronal function, which has high energy demands and requires precise protein homeostasis.

Understanding RPL32's functions provides opportunities for developing therapeutic strategies targeting translation and protein homeostasis in neurodegenerative diseases. Modulating RPL32 expression or function may help restore proper protein synthesis in affected neurons and support neuronal survival.

See Also

• [Ribosome Biogenesis](/mechanisms/ribosome-biogenesis)
• [Protein Synthesis](/mechanisms/protein-synthesis)
• [Translation Machinery](/mechanisms/translation-machinery)
• [Mitochondrial Function](/mechanisms/mitochondrial-function)
• [Mitochondrial Translation](/mechanisms/mitochondrial-translation)
• [Protein Homeostasis](/mechanisms/protein-homeostasis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia)

External Links

• [NCBI Gene: RPL32](https://www.ncbi.nlm.nih.gov/gene/6161)
• [UniProt: P62999](https://www.uniprot.org/uniprotkb/P62999/entry)
• [GeneCards: RPL32](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RPL32)
• [OMIM: 180468](https://www.omim.org/entry/180468)
• [Ensembl: ENSG00000137491](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137491)
• [Allen Brain Atlas: RPL32](https://human.brain-map.org/microarray/search/show?search_term=RPL32)

References